<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>作为您在 Google 上的首选新闻来源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>雅培（Abbott Laboratories，股票代码：ABT）周三宣布，其基于传感器的血糖监测技术 FreeStyle Libre 3 Plus 传感器现在在加拿大所有省份获得公共资金支持，这意味着更多糖尿病患者可以使用该血糖传感器。</p>
<p>该产品现在被联邦计划如非保险健康福利和大多数雇主赞助的工作场所福利计划覆盖。</p>
<p>雅培在加拿大糖尿病护理业务的总经理 Luz Herrera 评论道：“广泛的覆盖范围清楚地证明了我们技术的深远影响和价值。”</p>
<p>ABT 目前在纽约证券交易所的交易价格为 127.66 美元，下跌 0.15%。</p>
<p>,</p>
<p>如有意见和反馈，请联系：editorial@rttnews.com</p>
<p>商业新闻</p>

雅培

<p>雅培（Abbott Laboratories，股票代码：ABT）宣布其 FreeStyle Libre 3 Plus 血糖传感器现在在加拿大所有省份获得公共资金支持，从而提高了糖尿病患者的可及性。该传感器在联邦计划和大多数雇主赞助的福利下均有覆盖。雅培加拿大糖尿病护理总经理 Luz Herrera 强调了这一覆盖的重要性。ABT 的股票目前在纽约证券交易所交易价格为 127.66 美元，下跌 0.15%</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>作为您在 Google 上的首选新闻来源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>Abbott Laboratories (ABT), Wednesday announced that its sensor-based glucose technology, the FreeStyle Libre 3 Plus sensor, is now publicly funded in every province across Canada, meaning more people with diabetes can access the glucose sensor.</p>
<div class="lb-trans"><p>雅培（Abbott Laboratories，股票代码：ABT）周三宣布，其基于传感器的血糖监测技术 FreeStyle Libre 3 Plus 传感器现在在加拿大所有省份获得公共资金支持，这意味着更多糖尿病患者可以使用该血糖传感器。</p>
</div><p>The product is now covered under federal plans like Non-Insured Health Benefits and by a majority of employer-sponsored workplace benefits programs.</p>
<div class="lb-trans"><p>该产品现在被联邦计划如非保险健康福利和大多数雇主赞助的工作场所福利计划覆盖。</p>
</div><p>Luz Herrera, general manager of Abbott's diabetes care business in Canada, commented, &#34;The broad coverage is a clear testament to the deep impact and value of our technology.&#34;</p>
<div class="lb-trans"><p>雅培在加拿大糖尿病护理业务的总经理 Luz Herrera 评论道：“广泛的覆盖范围清楚地证明了我们技术的深远影响和价值。”</p>
</div><p>ABT is currently trading at $127.66, down 0.15 percent on the New York Stock Exchange.</p>
<div class="lb-trans"><p>ABT 目前在纽约证券交易所的交易价格为 127.66 美元，下跌 0.15%。</p>
</div><p>,</p>
<div class="lb-trans"><p>,</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如有意见和反馈，请联系：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商业新闻</p>
</div>

雅培实验室最新的葡萄糖传感器现已在加拿大获得公共资助